Newsfeeds - Spark Newswire

2 minute read

Freedom Biosciences Gets $10.5M In Seed Financing For Psychedelics Research, This Is What We Know

Today, 11:56 AM

Freedom Biosciences achieved a major $10.5 million in a seed financing round in which MBX Capital, PsyMed Ventures, Village Global and The Yale Startup, among others, participated.

BHVN

7 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For August 19, 2022

By Benzinga Insights

Today, 11:56 AM

Upgrades

AIRC

2 minute read

Why These Pfizer Analysts Like The Global Blood Therapeutics Deal

By Wayne Duggan

Today, 11:56 AM

Pfizer Inc. (NYSE: PFE) shares were trading lower Monday after the drugmaker announced a $5.4-billion bid to acquire blood disorder drugmaker Global Blood Therapeutics Inc (NASDAQ: GBT).

BHVN

1 minute read

Earnings

Recap: Biohaven Pharma Hldgs Q2 Earnings

By Benzinga Insights

Today, 11:56 AM

Biohaven Pharma Hldgs (NYSE:BHVN) reported its Q2 earnings results on Friday, August 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

BHVN

1 minute read

Biohaven Pharmaceutical Q2 EPS $(3.82) Down From $(2.62) YoY

By Benzinga Newsdesk

Today, 11:56 AM

Biohaven Pharmaceutical (NYSE:BHVN) reported quarterly losses of $(3.82) per share. This is a 45.8 percent decrease over losses of $(2.62) per share from the same period last year.

BHVN

6 minute read

FDA
News

Global Coalition For Adaptive Research, Biohaven, And Vigeo Announce Commencement Of Biohaven’s Troriluzole And Vigeo’s VT1021 In GBM AGILE Trial

By Benzinga Newsdesk

Today, 11:56 AM

Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven's Troriluzole and Vigeo'S VT1021 in GBM AGILE Trial Biohaven and Vigeo Now Enrolling in GBM AGILE, Registrational

BHVN

2 minute read

Earnings

Looking Into Biohaven Pharmaceutical’s Return On Capital Employed

By Benzinga Insights

Today, 11:56 AM

According to data from Benzinga Pro, during Q1, Biohaven Pharmaceutical's (NYSE:BHVN) reported sales totaled $318.85 million. Despite a 41.43% increase in earnings, the company posted a loss of $116.90 million.

BHVN

1 minute read

Biohaven Underscores Depth Of Migraine Portfolio With Data From Nurtec ODT Long-Term Open Label Study And Phase 3 Zavegepant Trial At 64th Annual Scientific Meeting Of The American Headache Society

By Benzinga Newsdesk

Today, 11:56 AM

31 new and encore presentations, including three late-breakers and three oral presentations, spotlight robust Nurtec ODT, zavegepant and migraine HEOR data Late-breaking submissions showcase new data for Nurtec ODT in

BHVN

1 minute read

Biohaven’s Neurological Disease Candidate Flunks In Late-Stage Study

By Vandana Singh

Today, 11:56 AM

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) has announced topline Phase 3 results of troriluzole in patients with spinocerebellar ataxia (SCA). The…

BHVN

3 minute read

FDA
News

Biohaven Pharmaceutical Announces FDA Has Filed And Accepted For Review A New Drug Application For Zavegepant Nasal Spray

By Benzinga Newsdesk

Today, 11:56 AM

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) today announced that the U.S. Food and Drug Administration (FDA) has filed and accepted for review a New Drug Application (NDA) for zavegepant nasal spray, the

BHVN